136 assets in B-Cell Acute Lymphoblastic Leukemia

Etoposide

Crisantaspase

Vincristine Sulfate

Dasatinib

Nivestim

Pegaspargase

Mercaptopurine Anhydrous

Asparaginase

Cyclophosphamide

Cytarabine

Daunomycin

Dexasone

Methotrexate

Blinatumomab

Inotuzumab Ozogamicin

Adriamycin

Hydrocortisone

Isocyclophosphamide

Prednisone

(+)-Vincristine

Brexucabtagene Autoleucel

cd19-ucart

Thioguanine Anhydrous

Nivolumab

Pegfilgrastim

cd22 car-transduced t cells

Prednisolone

Rituximab

Venetoclax

Cart-19 Cells

Anakinra

Fludarabine

Calaspargase Pegol

Levofolinic Acid

Tocilizumab

Diphenhydramine

Mitoxantrone

Imatinib

Tacrolimus

Anti-Cd19 Car T-Cells

Bendamustine

Allopurinol

Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Obtained By Apheresis Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector, Encoding A Chimeric Antigen Receptor (Car) Consisting Of An Anti-Cd19 Specific Scfv, A Cd8.Alpha. Stalk, Transmembrane Domain And Anchor, A 41Bb Endodomain And A Cd3 Zeta Endodomain, Under The Control Of A Human Pgk1 Promoter And A Modified Woodchuck Post Transcriptional Response Element. The Vector Genome Also Contains A 5' Terminal Cmv Enhancer/Promoter, A .Psi. Packaging Signal, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt)

Azacitidine

Dexrazoxane

Inaticabtagene Autoleucel

Ponatinib

Sirolimus

Tafasitamab

Avtozma